Biblio Discovery — Demo Discovery Service

16 hasil untuk "Robert Bissonnette"

Menampilkan 1–16 · 0,36 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris

    Robert Bissonnette; Mayte Suárez-Fariñas; Xuan Li dkk.

    PLOS ONE, Vol. 11 No. 5 · 2016 · Inggris · PLOS Scopus

    Introduction: There is a controversy surrounding the existence of palmoplantar pustulosis (PPP) and palmoplantar pustular psoriasis (PPPP) as separate clinical entities or as variants of the same clinical entity. We used gene expression microarray to compare gene expression in PPP and PPPP…

    Juga tersedia di: DOAJ

  2. Artikel Jurnal Teks lengkap

    Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council

    Yael Renert‐Yuval; Jacob Pontoppidan Thyssen; Robert Bissonnette dkk.

    Journal of Allergy and Clinical Immunology · 2021 · Inggris · OpenAlex Scopus

    Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic challenge with increasingly recognized different phenotypes among variable patient populations.Because therapeutic response may vary on the basis of heterogeneous clinical and molecular phenotypes, a shift toward…

  3. Artikel Jurnal

    Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies

    Eric L. Simpson; Robert Bissonnette; Zelma C. Chiesa Fuxench dkk.

    Journal of Dermatological Treatment, Vol. 35 No. 1 · 2024 · Inggris · DOAJ Scopus

    Purpose: Ruxolitinib (selective Janus kinase [JAK] 1 and JAK2 inhibitor) cream demonstrated efficacy and safety in patients with atopic dermatitis (AD) in the phase 3 TRuE-AD studies. In TRuE-AD1/TRuE-AD2 (NCT03745638/NCT03745651), adults and adolescents with mild to moderate AD were randomized to…

  4. Artikel Jurnal

    Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study

    A. David Burden; Robert Bissonnette; Alexander A. Navarini dkk.

    Dermatology and Therapy, Vol. 13 No. 10 · 2023 · Inggris · DOAJ Scopus

    Abstract Introduction We evaluated the anti-interleukin-36 receptor antibody spesolimab in patients with moderate-to-severe palmoplantar pustulosis (PPP). Methods This phase IIb trial comprised a loading dose period to week (W) 4, then maintenance dosing to W52. Patients were randomised 2:1:1:1:2…

  5. Artikel Jurnal Teks lengkap

    NOD2 Agonism Counter-Regulates Human Type 2 T Cell Functions in Peripheral Blood Mononuclear Cell Cultures: Implications for Atopic Dermatitis

    Vladimir-Andrey Gimenez-Rivera; Harshita Patel; Franck P. Dupuy dkk.

    Biomolecules, Vol. 13 No. 2 · 2023 · Inggris · DOAJ Scopus

    Atopic dermatitis (AD) is known as a skin disease; however, T cell immunopathology found in blood is associated with its severity. Skin Staphylococcus aureus (S. aureus) and associated host–pathogen dynamics are important to chronic T helper 2 (Th2)-dominated inflammation in AD, yet they remain…

  6. Artikel Jurnal

    The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial

    Robert Bissonnette; Ronald Vender; Andreas Pinter dkk.

    Journal of Dermatological Treatment, Vol. 36 No. 1 · 2025 · Inggris · DOAJ Scopus

    The objective was to investigate the reliability, validity, and meaningful change scores for the Physician’s Global Assessment of Hands and/or Feet (hf-PGA), a measure of clinician-reported psoriasis severity on the hands/feet. Baseline, Week 8, and Week 16 data were analyzed from adult patients…

  7. Artikel Jurnal

    Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a studyResearch in context

    Howard Sofen; Robert Bissonnette; Gil Yosipovitch dkk.

    EClinicalMedicine, Vol. 57 · 2023 · Inggris · DOAJ Scopus

    Summary: Background: Prurigo nodularis is a chronic skin disease characterised by intensely pruritic, hyperkeratotic nodules. Vixarelimab, a human monoclonal antibody, binds to the beta subunit of the oncostatin M receptor, inhibiting signalling of both interleukin 31 and oncostatin M, two cytokine…

  8. Artikel Jurnal

    Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies

    Marjolein De Bruin-Weller; Tilo Biedermann; Robert Bissonnette dkk.

    Acta Dermato-Venereologica, Vol. 101 No. 2 · 2021 · Inggris · DOAJ Scopus

    Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe atopic dermatitis exists. We sought to reach international consensus through an eDelphi process on a core set of recommendations for such an approach. Recommendations were developed by an…

  9. Artikel Jurnal

    International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale

    Amy S Paller; Emma Guttman-Yassky; Katrina Abuabara dkk.

    BMJ Open, Vol. 10 No. 11 · 2020 · Inggris · DOAJ Scopus

    Introduction As new topical and systemic treatments become available for atopic dermatitis (AD), there is a need to understand how treatments are being used in routine clinical practice, their comparative effectiveness and their long-term safety in diverse clinical settings.Methods and analysis The…

  10. Artikel Jurnal

    The Treat-to-Target Project in Atopic Dermatitis: One Year On

    Marjolein de Bruin-Weller; Mette Deleuran; Tilo Biedermann dkk.

    Acta Dermato-Venereologica, Vol. 103 · 2023 · Inggris · DOAJ Scopus

    Atopic dermatitis is a chronic skin condition for which a range of systemic treatments have recently been approved. A treat-to-target strategy has been developed previously alongside an algorithm to guide the management of patients with atopic dermatitis. Here, we review the strategy and algorithm…

  11. Artikel Jurnal

    Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis

    David Strawn; James G. Krueger; Robert Bissonnette dkk.

    JCI Insight, Vol. 10 No. 24 · 2025 · Inggris · DOAJ Scopus

    BACKGROUND Icotrokinra is the first and only targeted oral peptide that selectively binds the IL-23 receptor with high affinity to precisely inhibit IL-23 signaling. Icotrokinra demonstrated high rates of complete skin clearance and durable disease control in the phase IIb trial, FRONTIER-1, and…

  12. Artikel Jurnal

    Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling

    Kacey L. Sachen; Deepa Hammaker; Indra Sarabia dkk.

    Frontiers in Immunology, Vol. 16 · 2025 · Inggris · DOAJ Scopus

    IL-23 is implicated in the pathogenesis of immune-mediated inflammatory diseases, and myeloid cells that express Fc gamma receptor 1 (FcγRI or CD64) on their surface have been recently identified as a primary source of IL-23 in inflamed tissue. Our complementary analyses of transcriptomic datasets…